The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

A study led by the Vall d'Hebron Research Institute (VHIR) demonstrates the causal role of air pollution in ventricular arrhythmias and identifies a possible therapeutic strategy based on antioxidants.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.

The charitable initiative created in honor of Pol is supporting a research project aimed at identifying therapeutic targets to treat a rare type of leukemia.

The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The funds raised will contribute to ensuring the continuity of the pediatric brain tumor research line developed by the Vall d’Hebron research teams.

2025 has been an active year with the participation of RADeep members at the Data Access Committee at Vall d’Hebron and the presentation of abstracts at the 67th ASH Annual Meeting and Exposition.

Since 2019, Pulseras Candela has been collaborating with the Childhood Cancer and Hematological Diseases group at VHIR on the project “New Therapeutic Approaches for the Treatment of Pediatric Ependymoma.”

The session has helped bring the public an up-to-date perspective on diagnosis, treatments, and the research lines that are transforming the future of patients.

The donation will boost several lines of research to advance liquid biopsy in pediatric sarcomas and brain tumors.

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

The second edition of the AI ​​Day served to share knowledge, reflect and chart the future of artificial intelligence applied to research and health.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

The study, led by Vall d'Hebron, is the first in Spain to analyse the relationship between pregnancy complications and the risk of long-term cardiovascular diseases.

The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.